Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2-THE-TOP: Pembrolizumab + Optune + TMZ in Newly Diagnosed Glioblastoma
NCT03405792Phase 2Active, not recruiting
- Sponsor
- University of Florida
- Start
- Feb 2018
- Primary completion
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in glioblastoma (GBM) (2 arms), sponsored by University of Florida. Primary endpoint: Progression-Free Survival at 24 months. Started Feb 2018; status: active, not recruiting.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03405792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03405792.